股東特別大會之投票表決結果 香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） 董事會欣然宣佈，所有載於日期為二零二五年八月十二日之股東特別大會通告之決 議案已於二零二五年八月二十九日舉行之股東特別大會上正式通過。 股東特別大會結果 茲提述天津泰達生物醫學工程股份有限公司（「本公司」）之股東特別大會通告（「股東特 別大會通告」）及通函（「通函」），兩者日期均為二零二五年八月十二日。除文義另有所指 外，本公告所用詞彙與通函所界定者具相同涵義。 董事會（「董事會」）欣然宣佈，所有載於股東特別大會通告之決議案已於二零二五年八 月二十九日舉行之股東特別大會（「股東特別大會」）上按投票表決方式正式通過。 於股東特別大會日期，本公司有2,133,900,000股已發行股份，包括697,5 ...

[Cover and Disclaimer](index=1&type=section&id=Cover%20and%20Disclaimer) [GEM Features and Disclaimer](index=1&type=section&id=GEM%20Features%20and%20Disclaimer) This semi-annual report for Tianjin TEDA Biomedical Engineering Co., Ltd. on GEM is confirmed by directors as accurate, with the Stock Exchange disclaiming responsibility - GEM is positioned as a listing market for small and medium-sized companies with **high investment risk**, where securities may be subject to **significant market volatility**[2](index=2&type=chunk) - The company's directors jointly and individually assume **full responsibility** for the information in this announcement, confirming its **accuracy, completeness, and absence of misleading content**[2](index=2&type=chunk) [Summary](index=2&type=section&id=Summary) [Financial Highlights](index=2&type=section&id=Financial%20Highlights) Group turnover increased by 7.01% and gross profit by 14.07%, but loss attributable to equity holders expanded to RMB 6.43 million, with no dividend recommended 2025 H1 Financial Highlights | Indicator | 2025 H1 (RMB) | 2024 H1 (RMB) | Year-on-year Change | | :--- | :--- | :--- | :--- | | Consolidated Turnover | 226,407,014 | 211,568,049 | +7.01% | | Consolidated Gross Profit | 13,820,662 | 12,115,570 | +14.07% | | Loss Attributable to Equity Holders of the Company | (6,426,384) | (4,123,183) | Loss expanded | | Loss Per Share | 0.317 cents | 0.218 cents | Loss expanded | - The Board **does not recommend** the payment of a dividend for the six months ended June 30, 2025[4](index=4&type=chunk) [Semi-Annual Results (Unaudited)](index=3&type=section&id=Semi-Annual%20Results%20%28Unaudited%29) [Condensed Consolidated Income Statement](index=3&type=section&id=Condensed%20Consolidated%20Income%20Statement) Turnover increased to RMB 226.41 million and gross profit to RMB 13.82 million, but increased R&D and administrative expenses led to an expanded loss of RMB 8.43 million Condensed Consolidated Income Statement (For the six months ended June 30) | Indicator | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Turnover | 226,407,014 | 211,568,049 | | Cost of Sales | (212,586,352) | (199,452,479) | | Gross Profit | 13,820,662 | 12,115,570 | | Other Expenses and Losses / Income, Net | 235,587 | (50,195) | | Selling and Distribution Costs | (3,960,302) | (7,053,114) | | Research and Development and Administrative Expenses | (16,551,751) | (8,559,614) | | Finance Costs | (1,973,895) | (1,977,660) | | (Loss) / Profit Before Tax | (8,429,699) | (5,525,013) | | Income Tax | – | – | | (Loss) / Profit for the Period | (8,429,699) | (5,525,013) | | (Loss) / Profit for the Period Attributable to Owners of the Company | (6,426,384) | (4,123,183) | | (Loss) / Profit for the Period Attributable to Non-controlling Interests | (2,003,313) | (1,401,830) | | Loss Per Share - Basic (RMB) | 0.317 cents | 0.218 cents | [Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) Total assets increased to RMB 415.16 million, net current assets turned positive to RMB 29.71 million, and total equity grew to RMB 100.91 million Condensed Consolidated Statement of Financial Position (As of June 30) | Indicator | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Total Non-current Assets | 98,078,794 | 98,533,260 | | Total Current Assets | 317,084,756 | 233,993,789 | | Total Assets | 415,163,551 | 332,527,049 | | Total Current Liabilities | 287,372,895 | 279,065,167 | | Net Current Assets | 29,711,861 | (45,071,379) | | Total Non-current Liabilities | 26,884,872 | 25,021,945 | | Net Assets | 100,905,783 | 28,439,937 | | Equity Attributable to Owners of the Company | 96,618,228 | 22,149,069 | | Total Equity | 100,905,783 | 28,439,937 | [Condensed Consolidated Statement of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) Operating cash flow shifted to a net outflow of RMB 98.40 million, investing activities to a net inflow of RMB 6.72 million, and financing activities significantly increased to a net inflow of RMB 78.55 million Condensed Consolidated Statement of Cash Flows (For the six months ended June 30) | Indicator | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | (98,397,585) | 8,044,015 | | Net Cash From Investing Activities | 6,718,101 | (748,742) | | Net Cash From Financing Activities | 78,550,043 | 4,970,000 | | Net Change in Cash and Bank Balances | (13,129,441) | 12,265,273 | | Cash and Bank Balances at End of Period | 52,270,511 | 18,199,595 | - Net cash inflow from financing activities primarily resulted from the issuance of shares, amounting to **RMB 81,190,043**[8](index=8&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) [1. Basis of Presentation and Accounting Policies](index=7&type=section&id=1.%20Basis%20of%20Presentation%20and%20Accounting%20Policies) Financial statements are prepared under HKFRS and GEM Listing Rules on a going concern basis, with no significant impact from new standards - The financial statements are prepared under the **historical cost convention** and **Hong Kong Financial Reporting Standards**, on a **going concern basis**[9](index=9&type=chunk) - New and revised Hong Kong Financial Reporting Standards adopted during the period had **no significant impact** on the Group's unaudited operating results and financial position[9](index=9&type=chunk) [2. Revenue](index=7&type=section&id=2.%20Revenue) Total revenue reached RMB 226.41 million, with fertilizer products contributing RMB 182.99 million and elderly care and health business significantly growing to RMB 43.42 million Revenue Analysis (For the six months ended June 30) | Business Category | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Fertilizer Products | 182,987,005 | 211,314,827 | | Elderly Care and Health | 43,420,010 | 253,222 | | Total | 226,407,014 | 211,568,049 | - Revenue from elderly care and health business **significantly increased** from **RMB 253,222** in 2024 to **RMB 43,420,010** in 2025[10](index=10&type=chunk) [3. Finance Costs](index=7&type=section&id=3.%20Finance%20Costs) Finance costs, mainly bank loan interest and charges, totaled RMB 1.97 million, remaining largely consistent with the prior year Finance Costs (For the six months ended June 30) | Item | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Bank Loan Interest Expenses and Bank Charges | 1,973,895 | 1,977,660 | [4. Taxation](index=8&type=section&id=4.%20Taxation) Corporate income tax rate is 25%, with preferential rates for high-tech (15%) and small enterprises (5%), and zero income tax expense in Hong Kong and China - Guangdong Fulilong Compound Fertilizer Co., Ltd. enjoys a **15% preferential tax rate** as a high-tech enterprise[11](index=11&type=chunk) - Some Chinese subsidiaries qualify as small enterprises, enjoying a **5% preferential income tax rate**[11](index=11&type=chunk) Income Tax Expense (For the six months ended June 30) | Jurisdiction | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Hong Kong | – | – | | Other Jurisdictions | – | – | - Income tax expenses in Hong Kong and China were **zero** for the period[12](index=12&type=chunk) [5. Loss Per Share](index=9&type=section&id=5.%20Loss%20Per%20Share) Basic loss per share attributable to owners expanded to RMB 0.317 cents, up from RMB 0.218 cents, due to increased loss and weighted average shares Loss Per Share Calculation (For the six months ended June 30) | Indicator | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Loss for Calculation of Basic Loss Per Share | (6,426,384) | (4,123,183) | | Weighted Average Number of Ordinary Shares | 2,024,487,845 | 1,894,500,000 | [6. Additions to Property, Plant and Equipment](index=9&type=section&id=6.%20Additions%20to%20Property%2C%20Plant%20and%20Equipment) Expenditure on property, plant, and equipment additions was approximately RMB 834,918, an increase from the prior year - The Group's expenditure on additions to property, plant and equipment during the period was approximately **RMB 834,918** (2024: RMB 613,742)[16](index=16&type=chunk) [7. Trade and Bills Receivables](index=10&type=section&id=7.%20Trade%20and%20Bills%20Receivables) Net trade receivables significantly increased to RMB 34.22 million, driven by a rise in receivables aged within three months, with ongoing credit assessments Trade and Bills Receivables (As of June 30) | Item | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Trade Receivables, Net | 34,217,576 | 10,818,520 | Ageing Analysis of Trade Receivables (As of June 30) | Ageing | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Within 3 Months | 29,372,239 | 1,257,380 | | Over 3 Months but Within 6 Months | 62,237 | 3,717,203 | | Over 6 Months | 4,783,099 | 5,843,937 | [8. Prepayments and Other Receivables](index=11&type=section&id=8.%20Prepayments%20and%20Other%20Receivables) Total prepayments and other receivables increased to RMB 146.61 million, primarily driven by higher net other receivables and deposits and prepayments Prepayments and Other Receivables (As of June 30) | Item | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Other Receivables, Net | 12,749,745 | 3,490,539 | | Deposits and Prepayments | 133,859,849 | 78,976,908 | | Total | 146,609,595 | 82,467,447 | [9. Trade Payables](index=11&type=section&id=9.%20Trade%20Payables) Total trade payables significantly increased to RMB 33.08 million, mainly due to a notable rise in payables aged within three months Ageing Analysis of Trade Payables (As of June 30) | Ageing | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Within 3 Months | 27,782,169 | 2,180,601 | | Over 3 Months but Within 6 Months | 20,467 | 166,500 | | Over 6 Months | 5,281,368 | 6,584,577 | | Total | 33,084,003 | 8,931,678 | [10. Other Payables and Accruals](index=12&type=section&id=10.%20Other%20Payables%20and%20Accruals) Total other payables and accruals increased to RMB 81.59 million, primarily driven by an increase in other payables Other Payables and Accruals (As of June 30) | Item | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Other Payables | 58,578,315 | 31,008,970 | | Consideration for Acquisition of a Subsidiary | 2,206,900 | 2,206,900 | | Accruals | 4,141,108 | 6,278,834 | | Advances Received | 13,379,852 | 13,379,852 | | Amounts Due to Directors | 322,381 | 315,000 | | Social Welfare Fund Payable | 2,965,152 | 2,965,152 | | Total | 81,593,708 | 56,154,708 | [11. Share Capital](index=12&type=section&id=11.%20Share%20Capital) Authorized and issued share capital increased, with domestic shares growing significantly, bringing total par value to RMB 213.39 million Share Capital Structure (As of June 30) | Category | Number of Shares as of June 30, 2025 | Par Value as of June 30, 2025 (RMB thousands) | Number of Shares as of December 31, 2024 | Par Value as of December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | :--- | :--- | | Authorized Share Capital | 2,133,900,000 | 213,390 | 1,894,500,000 | 189,450 | | Issued and Fully Paid Domestic Shares | 1,436,400,000 | 143,640 | 697,500,000 | 69,750 | | Issued and Fully Paid H Shares | 697,500,000 | 69,750 | 1,197,000,000 | 119,700 | | Total | 2,133,900,000 | 213,390 | 1,894,500,000 | 189,450 | [12. Capital Commitments](index=12&type=section&id=12.%20Capital%20Commitments) The Group had no significant capital commitments not provided for in the condensed consolidated financial statements as of June 30, 2025 - As of June 30, 2025, the Group had **no significant capital commitments** not provided for in its condensed consolidated financial statements[23](index=23&type=chunk) [13. Contingent Liabilities](index=12&type=section&id=13.%20Contingent%20Liabilities) The company provided guarantees for bank facilities to subsidiaries amounting to RMB 0, consistent with the prior year - The company has provided guarantees for bank facilities granted to certain subsidiaries amounting to **RMB 0** (June 2024: RMB 0)[24](index=24&type=chunk) [Interim Dividend](index=13&type=section&id=Interim%20Dividend) The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 - The Board **does not recommend** the payment of an interim dividend for the six months ended June 30, 2025 (June 2024: nil)[25](index=25&type=chunk) [Condensed Consolidated Statement of Changes in Equity](index=13&type=section&id=Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Equity) Equity attributable to owners significantly increased from RMB 22.15 million to RMB 96.62 million, driven by share issuance despite a period loss Condensed Consolidated Statement of Changes in Equity (As of June 30) | Item | June 30, 2025 (RMB) | June 30, 2024 (RMB) | | :--- | :--- | :--- | | Balance at January 1 | 22,149,069 | 49,951,308 | | Net Profit Attributable to Equity Holders of the Company | (6,426,384) | (4,123,183) | | Issuance of Shares | 80,895,544 | 0 | | Balance at June 30 | 96,618,228 | 45,828,125 | - The issuance of shares resulted in an equity increase of **RMB 80,895,544**[26](index=26&type=chunk) [Management Discussion and Analysis](index=14&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review](index=14&type=section&id=Business%20Review) The Group operates in bio-compound fertilizers, AI medical elderly care, and data services, focusing on large medical models and comprehensive data solutions - The Group's three major business areas are **bio-compound fertilizers, AI medical elderly care, and data services**[27](index=27&type=chunk) - The AI medical elderly care business collaborates with hospitals under Peking University Health Science Center to develop serious medical large models based on **millions of real patient cases**[27](index=27&type=chunk) - The data business, as a core ecological partner of Shenzhen Institute of Advanced Computing, provides end-to-end services including **data cleaning, database construction, and intelligent data analysis**[27](index=27&type=chunk) [Compound Fertilizer Business](index=15&type=section&id=Compound%20Fertilizer%20Business) H1 2025 saw structural adjustments in compound fertilizer raw materials, with rising potash prices and stable downstream demand, while the Group's business covers diverse products with comprehensive management - In H1 2025, potash prices increased by **15%-20%**, becoming the primary driver of rising compound fertilizer costs[29](index=29&type=chunk) - Downstream demand for compound fertilizers remained stable with progress, showing **strong resilience and vitality** in the economic crop sector[29](index=29&type=chunk) - The Group's compound fertilizer products include high-tower compound fertilizers, sulfur-based, chlorine-based, and nitrate-based types, characterized by **high nutrient content and environmental friendliness**[32](index=32&type=chunk) - Through informatization, the Group has established a comprehensive operational management model across five business segments: **procurement, production, marketing, logistics, and finance**[32](index=32&type=chunk) [Compound Fertilizer Industry Development](index=15&type=section&id=Compound%20Fertilizer%20Industry%20Development) H1 2025 saw structural adjustments in raw materials, with nitrogen prices falling, potash rising, and compound fertilizer prices fluctuating, while downstream demand remained resilient - Nitrogen fertilizer prices showed an overall **downward trend** in H1, constrained by overcapacity and export restrictions[29](index=29&type=chunk) - Tight potash supply dominated the market, with a **15%-20% increase** in H1, becoming the core driver of rising compound fertilizer costs[29](index=29&type=chunk) - Compound fertilizer prices exhibited a divergent trend of "**rising in Q1 and high-level fluctuations in Q2**"[29](index=29&type=chunk) - Downstream demand remained stable with progress, showing **extremely strong resilience and vitality** in the economic crop sector[29](index=29&type=chunk) - Market trends necessitate fertilizer enterprises to continuously **research and develop new products**, improve product quality and efficacy, and strengthen environmental protection facilities[31](index=31&type=chunk) [Group's Compound Fertilizer Business Development](index=16&type=section&id=Group%27s%20Compound%20Fertilizer%20Business%20Development) The Group's compound fertilizer business offers diverse products for various crops, supported by strategic procurement, sales-driven production, and multi-channel distribution - Products primarily include **high-tower compound fertilizers**, categorized by nutrient source (**sulfur-based, chlorine-based, nitrate-based**) and type (**high-concentration, micro-element, water-soluble, slow/controlled-release, seaweed, bio-fertilizers, crop-specific, horticultural fertilizers**)[32](index=32&type=chunk) - Procurement models include **strategic procurement and order-based procurement**, establishing long-term partnerships with major raw material suppliers[33](index=33&type=chunk) - Production is **sales-driven**, with bases in Weifang, Shandong and Dongguan, Guangdong, and expanded offerings of liquid and water-soluble compound fertilizers to meet market demand[33](index=33&type=chunk) - Marketing primarily uses **distributor networks**, established the well-known brand "Fulilong", and built e-commerce sales platforms[33](index=33&type=chunk) [AI Medical Elderly Care Business](index=18&type=section&id=AI%20Medical%20Elderly%20Care%20Business) The Group manages 50 elderly care institutions under 'Ruifu Elderly Care' and, through share placements and collaboration with Peking University, developed the bilingual 'Xihe-1' AI medical large model, trained on millions of real patient cases - The Group's core elderly care team has been engaged in elderly care since 1999, establishing the "**Ruifu Elderly Care**" brand and managing **50 elderly care institutions in Shanghai**[34](index=34&type=chunk) - In H1 2025, two rounds of share placements were completed, raising net proceeds of approximately **HKD 88.8 million** for purchasing and developing AI medical health software platforms[35](index=35&type=chunk) - Collaborated with hospitals under Peking University Health Science Center to establish Beijing Boya Quan Jian Smart Computing Technology Co., Ltd., focusing on the deep integration of **artificial intelligence and medical health technology**[36](index=36&type=chunk) - Jointly developed the bilingual "**Xihe-1**" medical large model with Peking University Third Hospital over ten years, trained on **millions of real patient cases** using closed-source data, achieving an accuracy rate of **over 90%**[37](index=37&type=chunk) - Key advantages of "**Xihe-1**" include training on closed data, **pathology evidence-driven decision-making**, and a dual engine of "**natural language interaction + traceable knowledge reasoning**" empowering clinical decisions[37](index=37&type=chunk)[38](index=38&type=chunk) - Jointly developed the "**Xihe-1**" pre-diagnosis and triage integrated machine with Xiamen Hongxin Electronics Technology Group subsidiary Suihong Huachuang, with plans for focused promotion in **grassroots medical care**[38](index=38&type=chunk) [Data Business](index=21&type=section&id=Data%20Business) The Group established Shenzhen Yishu Jingcheng Technology Co., Ltd. for data governance, providing high-quality data for AI medical models and full-process data services to clients, supported by strategic partnerships - Established controlling subsidiary Shenzhen Yishu Jingcheng Technology Co., Ltd. as an officially certified **core ecological partner of Shenzhen Institute of Advanced Computing**, engaging in data governance[40](index=40&type=chunk) - Yishu Jingcheng provides **high-quality data** for the company's AI medical large model training and offers external clients end-to-end services including **data cleaning, intelligent analysis, and customized model training**[40](index=40&type=chunk) - Achieved strategic cooperation with Peking University Third Hospital to jointly develop "**Xihe-1**" and acquire **millions of real patient cases** of closed-source medical data for training[40](index=40&type=chunk) - Signed a strategic cooperation agreement with China Telecom Digital Intelligence Technology Co., Ltd. Ningxia Branch to jointly build a **medical health ecosystem platform** and an "**AI + Medical Health**" industrial park[41](index=41&type=chunk) - Signed an ecological cooperation agreement with Shenzhen Institute of Advanced Computing, where Yishu Jingcheng handles client engagement and demand identification, and Shenzhen Institute of Advanced Computing provides technical support including **Yashan Database, Caishiqi Data Quality System, and Diaoyucheng Data Analysis System**[41](index=41&type=chunk) [Financial Performance Review](index=24&type=section&id=Financial%20Performance%20Review) Turnover grew 7.01%, gross profit 14.07%, and gross margin to 6.10%, but a 93.37% surge in R&D and administrative expenses led to an expanded loss Key Financial Indicators Change (For the six months ended June 30) | Indicator | 2025 (RMB) | 2024 (RMB) | Year-on-year Change | | :--- | :--- | :--- | :--- | | Total Turnover | 226,407,014 | 211,568,049 | +7.01% | | Consolidated Gross Profit | 13,820,662 | 12,115,570 | +14.07% | | Operating Consolidated Gross Profit Margin | 6.10% | 5.73% | +0.37% | | Selling and Distribution Costs | 3,960,302 | 7,053,114 | -43.85% | | Research and Development and Administrative Expenses | 16,551,751 | 8,559,614 | +93.37% | | Finance Costs | 1,973,895 | 1,977,660 | -0.19% | | Loss Attributable to Equity Holders of the Company | 6,426,384 | 4,123,183 | Loss expanded | - The growth in operating revenue was primarily attributable to the **rapid development of the elderly care and health business segment**[42](index=42&type=chunk) - The decrease in selling and distribution costs was mainly due to **strengthened expense control**, achieving cost reduction and efficiency improvement through travel expense reimbursement system reform and refined channel management[43](index=43&type=chunk) [Liquidity, Financial Resources and Capital Structure](index=25&type=section&id=Liquidity%2C%20Financial%20Resources%20and%20Capital%20Structure) Bank and cash balances were RMB 52.27 million, short-term borrowings decreased, total assets and equity grew, and financial health improved with lower debt ratios and a current ratio of 1.10 Liquidity and Capital Structure Indicators (As of June 30) | Indicator | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Bank and Cash Balances | 52,270,511 | 65,399,950 | | Short-term Borrowings | 83,830,000 | 134,670,000 | | Total Assets | 415,163,551 | 332,527,049 | | Shareholders' Equity | 100,905,783 | 28,439,937 | | Consolidated Debt-to-Asset Ratio | 0.76 | 0.91 | | Capital-to-Debt Ratio | 0.24 | 0.45 | | Current Ratio | 1.10 | 0.84 | - Primary funding sources were **bank financing and proceeds from share placements**[47](index=47&type=chunk) - Short-term borrowing interest rates ranged from **2.90% to 3.55%**[47](index=47&type=chunk) [Pledges of Assets and Contingent Liabilities](index=25&type=section&id=Pledges%20of%20Assets%20and%20Contingent%20Liabilities) As of June 30, 2025, the Group and company had contingent liabilities of RMB 0 for pledges and guarantees related to subsidiary bank loans - As of June 30, 2025, the Group and the company had contingent liabilities of **RMB 0** for pledges and guarantees provided for bank loans granted to its subsidiaries[49](index=49&type=chunk) [Foreign Currency Risk](index=25&type=section&id=Foreign%20Currency%20Risk) Foreign currency risk is minimal as all Group sales and payments are settled in RMB - All the Group's sales and payments are settled in **RMB**, thus the foreign currency risk faced is **minimal**[50](index=50&type=chunk) [Treasury Policy](index=25&type=section&id=Treasury%20Policy) Bank borrowings are RMB-settled and typically renewed annually, with cash balances deposited in licensed Chinese banks - The Group's bank borrowings are settled in **RMB** and generally **renewed for one year** upon maturity[51](index=51&type=chunk) - Any cash balances are deposited as funds in **licensed banks in China**[51](index=51&type=chunk) [Outlook](index=26&type=section&id=Outlook) The company will focus on R&D and commercialization of AI medical large models and data businesses, deepening partnerships to enhance existing elderly care services with AI - The company will continue to fully commit to the **R&D and commercialization** of AI medical large models and data businesses[52](index=52&type=chunk) - Deepen cooperation with top-tier hospitals like Peking University Third Hospital and Peking University People's Hospital, utilizing **real patient case data for model training**[52](index=52&type=chunk) - Deepen cooperation with Shenzhen Institute of Advanced Computing, providing **end-to-end data services** for medical institutions, enterprises, government departments, and industry AI applications[52](index=52&type=chunk) - Deeply empower existing elderly care services with AI medical technology to **enhance service efficiency and quality**[52](index=52&type=chunk) [Other Information](index=26&type=section&id=Other%20Information) [Directors' and Supervisors' Interests in Shares, Related Shares and Debentures](index=26&type=section&id=Directors%27%20and%20Supervisors%27%20Interests) As of June 30, 2025, no directors, supervisors, or senior executives held notifiable interests or short positions in the company's or its associated corporations' securities - As of June 30, 2025, **none** of the company's directors, supervisors, or other senior executives held any **notifiable interests or short positions** in the securities, related shares, or debentures of the company or its associated corporations that require notification to the company and the Stock Exchange[53](index=53&type=chunk) [Rights to Acquire Shares by Directors and Supervisors](index=27&type=section&id=Rights%20to%20Acquire%20Shares%20by%20Directors%20and%20Supervisors) No arrangements existed during the review period for directors, supervisors, or their associates to acquire benefits by purchasing company shares - At no time during the review period did the company, its subsidiaries, or holding companies enter into **no arrangements** enabling the company's directors and supervisors, or their respective spouses or children under 18, to acquire benefits by purchasing the company's shares[54](index=54&type=chunk) [Major Shareholders](index=27&type=section&id=Major%20Shareholders) As of June 30, 2025, three major shareholders each held over 9.50% equity, with another holding 6.33% Major Shareholders' Shareholding (As of June 30) | Shareholder Name | Capacity | Number of Ordinary Shares | Percentage of Share Capital | | :--- | :--- | :--- | :--- | | Tianjin Economic-Technological Development Area State-owned Assets Management Co., Ltd. | Beneficial Owner | 182,500,000 | 9.63% | | Shenzhen Xiangyong Investment Co., Ltd. | Beneficial Owner | 180,000,000 | 9.50% | | Shenzhen Aopai Technology Co., Ltd. | Beneficial Owner | 180,000,000 | 9.50% | | Dongguan Luye Fertilizer Co., Ltd. | Beneficial Owner | 120,000,000 | 6.33% | - All disclosed shares are **domestic shares**[55](index=55&type=chunk) [Competing Interests](index=28&type=section&id=Competing%20Interests) No directors, supervisors, management shareholders, or their associates had any competing interests or conflicts of interest with the Group's business during the period - For the six months ended June 30, 2025, none of the company's directors, supervisors, or management shareholders and their respective associates had any existing or potential **no competing interests** with the Group's business, or any other existing or potential **no other conflicts of interest** with the Group[57](index=57&type=chunk) [Audit Committee](index=28&type=section&id=Audit%20Committee) The Audit Committee, chaired by Ms. Gao Chun and comprising three independent non-executive directors, reviews financial reporting, external audit, internal controls, and risk assessment, having reviewed the interim results - The Audit Committee comprises three independent non-executive directors: Mr. Tu Xiangzhen, Mr. Wang Yongkang, and Ms. Gao Chun, with **Ms. Gao Chun as Chairperson**[58](index=58&type=chunk) - The Committee's primary responsibilities include **reviewing and overseeing the Group's financial reporting process**, and assessing the effectiveness of **external audit, internal controls, and risk assessment**[58](index=58&type=chunk) - The Audit Committee has **reviewed the Group's interim results and interim report** for the six months ended June 30, 2025[58](index=58&type=chunk) [Share Option Scheme](index=28&type=section&id=Share%20Option%20Scheme) The company did not approve any new share option schemes during the period ended June 30, 2025 - During the period ended June 30, 2025, the company **did not approve any new share option schemes**[59](index=59&type=chunk) [Contracts of Significance](index=29&type=section&id=Contracts%20of%20Significance) During H1 2025, the company had no contracts of significance regarding the management or administration of its overall or major businesses - During H1 2025, the company had **no contracts of significance** regarding the management or administration of its overall business or any major business[60](index=60&type=chunk) [Code of Conduct for Securities Transactions by Directors](index=29&type=section&id=Code%20of%20Conduct%20for%20Securities%20Transactions%20by%20Directors) The company adopted a directors' securities transaction code no less stringent than GEM Listing Rules, confirming no non-compliance during the review period - The company has adopted a code of conduct with terms **no less stringent** than the required dealing standards set out in Rules 5.48 to 5.67 of the GEM Listing Rules[61](index=61&type=chunk) - The company is **unaware of any non-compliance** by directors with the required dealing standards and its code of conduct for securities transactions during the review period[61](index=61&type=chunk) [Purchase, Sale or Redemption of Securities](index=29&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Securities) In H1 2025, the company completed two share placements, raising HKD 88.8 million for AI medical software and working capital, with no other share transactions - On February 19, 2025, one round of share placement was completed, allotting **135,900,000 shares** and raising net proceeds of approximately **HKD 50.5 million**, for purchasing and developing AI medical health software platforms and working capital[62](index=62&type=chunk) - On May 8, 2025, a new round of share placement was completed, allotting **103,500,000 shares** and raising net proceeds of approximately **HKD 38.3 million**, for medical health software platform development, working capital, and potential investment opportunities[62](index=62&type=chunk) - Other than the aforementioned placements, neither the company nor its subsidiaries **purchased, sold, or redeemed any shares** during the period[62](index=62&type=chunk) [Corporate Governance Code](index=30&type=section&id=Corporate%20Governance%20Code) The company complied with all Corporate Governance Code provisions except for the non-separation of Chairman and CEO roles, which the Board deems in the company's best interest for now - The company complied with all provisions of the Code during the review period, **except for Code Provision A.2.1** (which states that the roles of chairman and chief executive should be separate)[63](index=63&type=chunk) - The Board believes that Ms. Sun Li concurrently holding the roles of Chairperson and Chief Executive Officer is currently in the company's **best interest**, facilitating policy continuity and operational stability[63](index=63&type=chunk) - The company will **comply with Code Provision A.2.1 as soon as practicable** to enhance corporate governance transparency and independence[63](index=63&type=chunk) [Interim Dividend (Reiteration)](index=30&type=section&id=Interim%20Dividend%20%28Reiteration%29) The Board resolved not to declare any interim dividend for the six months ended June 30, 2025 - The Board resolved **not to declare any interim dividend** for the six months ended June 30, 2025[64](index=64&type=chunk) [Board and Contact Information](index=30&type=section&id=Board%20and%20Contact%20Information) This announcement, published by Chairperson Ms. Sun Li on August 29, 2025, lists directors and provides GEM and company website access information - This announcement was published by Ms. Sun Li, Chairperson of the Board, on **August 29, 2025**[65](index=65&type=chunk)[66](index=66&type=chunk) - The company's executive director is **Sun Li**; non-executive directors are **He Xin, Li Xueying, and Li Ximing**; independent non-executive directors are **Tu Xiangzhen, Wang Yongkang, and Gao Chun**[66](index=66&type=chunk)

Core Viewpoint - The strategic cooperation agreement between Teda Biomedical and Suihong Huachuang Technology aims to leverage each other's resources, talent, and technology in the AI healthcare sector, focusing on specialized operations and market promotion [1][2] Group 1: Strategic Cooperation - Teda Biomedical has signed a strategic cooperation agreement with Suihong Huachuang Technology to enhance AI healthcare and data business operations [1] - The collaboration will focus on building intelligent computing centers and providing heterogeneous computing hardware solutions [1] - The partnership aims to ensure stable and efficient computing resources, which are crucial for the development and commercialization of AI healthcare models [1] Group 2: Resource and Technology Synergy - The agreement allows for complementary advantages in resources and technology between Teda Biomedical and Suihong Huachuang [2] - Suihong Huachuang's established government partnerships and sales channels will support Teda Biomedical's market promotion efforts for AI healthcare models [2] - The core technological capabilities of Suihong Huachuang in computing infrastructure and hardware manufacturing will provide stable computing support and cost-effective solutions for Teda Biomedical [2]

Core Viewpoint - The strategic cooperation agreement between Teda Biomedical and Suihong Huachuang Technology aims to leverage each other's resources and technological advantages in the AI healthcare sector, focusing on specialized operations and market promotion of AI medical health and data businesses [1][2]. Group 1: Strategic Cooperation - The partnership will enhance resource and technology synergies, utilizing Suihong Huachuang's established government collaborations and sales channels to support Teda Biomedical's AI medical model and related data business market promotion [2]. - Suihong Huachuang's core technological capabilities in AI computing infrastructure and hardware manufacturing will provide stable and efficient computing power for Teda Biomedical's AI medical model training and real-world application [2]. Group 2: Business Development Focus - Teda Biomedical is actively advancing the research and commercialization of AI medical models and related data businesses, emphasizing the importance of high-quality computing resources, stable hardware solutions, and extensive market promotion channels [1]. - The company plans to engage in resource alignment and cooperation discussions to ensure the sustainable and steady advancement of its business [1].

Core Viewpoint - The strategic cooperation agreement between Teda Bio and Shanghai Suihonghuachuang Technology Co., Ltd. aims to leverage their respective resources, talents, and technological advantages in the AI healthcare sector, focusing on specialized operations and market promotion [1][2]. Group 1: Strategic Cooperation - The partnership will enhance resource and technology synergies, utilizing Suihonghuachuang's established government collaborations and sales channels to support Teda Bio's AI healthcare model and data business market promotion [2]. - The collaboration will provide stable and efficient computing power and cost-effective hardware solutions, which are crucial for optimizing AI healthcare model training and facilitating commercial application [2]. Group 2: Business Development Focus - Teda Bio is actively advancing its AI healthcare model and related data business, emphasizing the importance of high-quality computing resources, stable hardware solutions, and extensive market promotion channels for effective business development [1]. - The company plans to engage in resource alignment and cooperation discussions to ensure sustainable and robust business growth [1].

香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） 自願公告 簽署AI醫療健康領域戰略合作協議 本公告由天津泰達生物醫學工程股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發，以向本公司股東及潛在投資者提供有關本集團的最新業務進度的信息。 簽署AI醫療健康領域戰略合作協議 本公司董事（「董事」）會（「董事會」）欣然宣佈，近期本公司與A股上市公司廈門弘信電 子科技集團股份有限公司（股票代碼：300657）之附屬公司上海燧弘華創科技有限公司 （「燧弘華創」）簽署AI醫療健康領域戰略合作協議（「合作協議」）。雙方將充分發揮各自 資源、人才和技術優勢，圍繞AI醫療健康和數據業務的專業化運營和市場推廣，醫療健 康領域的智算中心建設和算力提供，及多元異構算力硬件整體解決方 ...

Group 1: Event Overview - The 31st China International Medical Instrument and Equipment Exhibition and Technology Exchange Conference (China-Hospeq) was held from August 15 to 17 in Beijing, showcasing cutting-edge medical technology and serving as a catalyst for health industry transformation [1] - The National Health Commission announced the establishment of the "China-Africa Hospital Alliance" during the event, launching several joint working groups including "Health Silk Road AI Development" [1] Group 2: Strategic Collaborations - A seminar titled "Walking with AI: Health Silk Road AI Empowerment" was successfully held, where Hongxin Electronics' Chairman Li Qiang revealed a collaboration with Boya Quan Jian Technology to develop an integrated diagnostic machine for medical scenarios [1][3] - The integrated diagnostic machine aims to achieve efficient adaptation between domestic computing platforms and NVIDIA's Clara medical AI model, showcasing it at the exhibition [1][3] Group 3: Technological Innovations - Suihong Huachuang, a subsidiary of Hongxin Electronics, has built a comprehensive AI development system based on the national strategy of "National Core, National Model, National Use," providing end-to-end services from chip sourcing to application development [2] - The collaboration between Suihong Huachuang and Boya Quan Jian represents a significant step towards integrating computing power with medical applications, addressing challenges in data processing and algorithm execution [2][3] Group 4: AI Model Development - Boya Quan Jian's "Xihe No. 1" medical model, developed over nearly 10 years with 1 million real case data, boasts a 98% medical knowledge coverage and over 90% accuracy in disease prediction and personalized treatment [3] - The collaboration aims to bridge the gap in medical resource allocation, particularly in grassroots medical institutions facing computing power shortages [3][4] Group 5: Market Impact and Future Prospects - The integrated diagnostic machine is positioned as a key solution for achieving equitable distribution of medical resources, with a focus on enhancing diagnostic accuracy for prevalent diseases in Africa [4][7] - The strategic partnership is expected to create a replicable commercial pathway in the AI medical field, significantly lowering operational costs and enhancing service quality [6][7] - The initiative aims to serve over 100 million patients within three years and establish a global medical AI collaboration network [7]

Group 1: Event Overview - The 31st China International Medical Instrument and Equipment Exhibition and Technology Exchange Conference (China-Hospeq) will be held in Beijing from August 15 to August 17, 2025 [1] - The "China-Africa Hospital Alliance" was officially launched on August 16, initiated by the National Health Commission, Peking University Third Hospital, and Boya Health Technology [1][2] - The bilingual medical model "Xihe No. 1," valued at hundreds of billions, has signed a contract with the Ningxia Health Commission to address urgent medical needs in Africa [1][2] Group 2: AI Empowerment in Healthcare - The seminar "AI in Healthcare: Empowering the Health Silk Road" marks a new phase in China-Africa medical cooperation, emphasizing AI integration [2] - Tianjin TEDA Biomedical Engineering Co., Ltd. is building an AI + healthcare ecosystem that connects data, models, and clinical needs, particularly suited for Africa's diverse healthcare demands [2][4] - The "Xihe No. 1" model aims to address the critical shortage of medical resources in Africa by replicating the expertise of top doctors through AI [4][5] Group 3: Historical Context and Achievements - Over the past 60 years, China has sent more than 23,000 medical personnel to 53 African countries, built over 130 medical institutions, and treated over 280 million patients [3] - The establishment of the "China-Africa Hospital Alliance" aims to enhance medical service capabilities in Africa through direct hospital collaboration [3][4] Group 4: Challenges in African Healthcare - The misdiagnosis and missed diagnosis rates for cardiovascular diseases in Africa exceed 25%, with a significant shortage of medical professionals [4] - AI-assisted diagnosis can effectively mitigate the issues of insufficient medical personnel and enhance diagnostic accuracy [4][5] Group 5: Development and Capabilities of "Xihe No. 1" - "Xihe No. 1" was developed over nearly 10 years, utilizing 1 million real clinical cases, achieving 100 billion parameters, and supporting various medical applications [5][6] - The model has been integrated into Ningxia's "Internet + Healthcare" demonstration zone, enabling real-time data interaction and improving patient survival rates [6][7] Group 6: Future Prospects and Collaborations - The company aims to serve over 100 million patients within three years and establish a global medical AI collaboration network [9] - Continuous exploration and collaboration in the AI + healthcare sector will contribute to optimizing medical resource allocation and improving public health [9][8]

Group 1 - The 31st China International Medical Instrument and Equipment Exhibition and Technology Exchange Conference will be held from August 15 to August 17, 2025, in Beijing, focusing on AI technology applications in healthcare [1] - The seminar titled "Walking with AI: Health Silk Road AI Empowerment" aims to break down medical resource barriers and promote efficient collaboration among medical resources across regions and countries [2] - The "Xihe No. 1" medical model, developed by Peking University Third Hospital and other partners, has been trained on 1 million real clinical cases, achieving over 100 billion parameters and high accuracy in medical knowledge [3][4] Group 2 - The "Xihe No. 1" model is built on rigorous clinical data, ensuring low error rates and high compliance, which is crucial for its commercial application [4] - The model addresses significant issues in cardiovascular disease diagnosis, such as high misdiagnosis rates and delays in treatment, by providing a core research system focused on clinical needs [5] - The company aims to create an AI + healthcare ecosystem that spans various fields, including omics research and drug development, while also exploring AI-enabled hardware products [6] Group 3 - The company, Tianjin TEDA Biomedical Engineering Co., Ltd., is committed to enhancing global healthcare through AI and has established a strong innovation capability in medical data platform construction and resource collaboration [8] - A recent partnership with Shenzhen Computing Science Research Institute aims to improve data quality and analysis for AI medical model optimization [8] - The company anticipates serving over 100 million patients within three years and aims to establish a global AI collaboration network for shared medical wisdom [9]

Group 1 - The 31st China International Medical Instrument and Equipment Exhibition and Technical Exchange Conference will be held in Beijing from August 15 to August 17, 2025, featuring a seminar on AI in healthcare [1] - The seminar aims to leverage AI technology to create a "Health Silk Road," breaking down barriers in medical resource allocation and enhancing the efficiency of healthcare services across regions [2] - Multiple initiatives were launched during the seminar, including the establishment of a global children's early diagnosis and treatment AI innovation ecosystem, contributing to the construction of the "Health Silk Road" [2] Group 2 - The "Xihe No. 1" medical model, developed by Peking University Third Hospital and other partners, has been a focal point, utilizing 1 million real clinical cases and featuring over 100 billion parameters [3] - The model's training data comes from 18 medical institutions, ensuring high accuracy and compliance, with a medical knowledge coverage rate of 98% and precision rate exceeding 90% [4] - The model aims to address high misdiagnosis rates in cardiovascular diseases and improve diagnostic efficiency in primary care settings [5] Group 3 - The company is building an AI + healthcare ecosystem that encompasses data, models, and clinical applications, focusing on rapid translation of research outcomes into practical applications [6] - The company is also exploring AI-enabled hardware products to meet healthcare service demands, indicating a broadening of its service offerings [6] - The company has formed strategic partnerships to enhance data quality and application in AI medical models, aiming to serve over 100 million patients within three years [8][9]